Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30418396 | 1.00 | TSHR (0.40) | TSHRACHELMNAALOX12HPGDS | |
| Hydrochloric Acid SCHEMBL150092 | 0.97 | TSHR (0.38) | TSHRACHELMNAALOX12HPGDS | |
| Water SCHEMBL17220159 | 0.97 | TSHR (0.38) | TSHRACHELMNAALOX12HPGDS | |
| Water SCHEMBL1461353 | 0.97 | TSHR (0.38) | TSHRACHELMNAALOX12HPGDS | |
| SCHEMBL29035078 | 0.97 | TSHR (0.38) | TSHRACHELMNAALOX12HPGDS | |
| Hydrochloric Acid SCHEMBL30018178 | 0.97 | TSHR (0.38) | TSHRACHELMNAALOX12HPGDS | |
| Hydrochloric Acid SCHEMBL28785708 | 0.95 | TSHR (0.36) | TSHRACHELMNAALOX12HPGDS | |
| Hydrochloric Acid SCHEMBL30492120 | 0.95 | TSHR (0.36) | TSHRACHELMNAALOX12HPGDS | |
| Benzene SCHEMBL1522440 | 0.91 | DAO (0.40) | TSHRACHELMNAALOX12HPGDS | |
| SCHEMBL9413954 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 557 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115200-A1 | Treatments Using Methylthioninium Salt, Liquid Mineral Blends, and/or Secondary Physiologically Active Compounds With Physiological Therapies | BEST 365 LABS INC (US) | 2026-04-30 | — | — | US | claimed |
| US-20260083747-A1 | COMPOSITIONS AND METHODS FOR SUPPORTING MITOCHONDRIAL HEALTH | LOPEZ DARREN (US) | 2026-03-26 | — | — | US | claimed |
| US-20260048066-A1 | TREATMENT OF NEURODEGENERATIVE DISORDERS UTILISING METHYLTHIONINIUM (MT)-CONTAINING COMPOUNDS | WISTA LABORATORIES LTD (SG) | 2026-02-19 | — | — | US | claimed |
| EP-4385512-B1 | OPTIMISED DOSAGE OF DIAMINOPHENOTHIAZINES IN POPULATIONS | TAURX THERAPEUTICS MAN LTD (GB) | 2025-12-03 | — | — | EP | claimed |
| EP-4364801-B1 | OPTIMISED DOSAGE OF DIAMINOPHENOTHIAZINES IN POPULATIONS | TAURX THERAPEUTICS MAN LTD (GB) | 2025-11-12 | — | — | EP | claimed |
| US-20250302843-A1 | OPTIMISED DOSAGE OF DIAMINOPHENOTHIAZINES IN POPULATIONS | WISTA LABORATORIES LTD. (SG) | 2025-10-02 | — | — | US | claimed |
| US-20250275980-A1 | METHYLTHIONINIUM SALT-CONTAINING COMPOSITIONS AND METHODS | LOPEZ DARREN (US) | 2025-09-04 | — | — | US | claimed |
| EP-4335517-B1 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | WISTA LAB LTD (SG) | 2025-08-27 | — | — | EP | claimed |
| US-20250262219-A1 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | WISTA LABORATORIES LTD. (SG) | 2025-08-21 | — | — | US | claimed |
| US-20250222005-A1 | METHYLENE BLUE CONTAINING COMPOUNDS FOR THE TREATMENT OF METHAEMOGLOBINAEMIA | Wis Ta Laboratories Ltd. (SG) | 2025-07-10 | — | — | US | claimed |
| EP-2645994-B1 | FORMULATIONS COMPRISING METHYLTHIONINIUM CHLORIDE | WISTA LAB LTD (SG) | 2017-11-01 | — | — | EP | claimed |
| CN-106604728-A | Compositions for photodynamic control of infection | 普尔伯格有限公司 | 2017-04-26 | — | — | CN | claimed |
| EP-2480541-B1 | CRYSTALLINE METHYLTHIONIUM CHLORIDE (METHYLENE BLUE) HYDRATES | WISTA LAB LTD (SG) | 2015-11-04 | — | — | EP | claimed |
| EP-2046767-B1 | PROCESS FOR PREPARING DIAMINOPHENOTHIAZINIUM COMPOUNDS | PROVENCE TECHNOLOGIES (FR) | 2015-04-22 | — | — | EP | claimed |
| EP-2457904-B1 | Methods of synthesis and/or purification of diaminophenothiazinium compounds | WISTA LAB LTD (SG) | 2014-11-19 | — | — | EP | claimed |
| EP-2057136-B1 | METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS | WISTA LAB LTD (SG) | 2013-05-22 | — | — | EP | claimed |
| EP-1610829-B1 | TISSUE-ADHESIVE FORMULATIONS | TISSUEMED LTD (GB) | 2010-01-20 | — | — | EP | claimed |
| EP-2046767-A2 | PROCESS FOR PREPARING DIAMINOPHENOTHIAZINIUM COMPOUNDS | Provence Technologies (FR) | 2009-04-15 | — | — | EP | claimed |
| WO-2008006979-A2 | PROCESS FOR PREPARING DIAMINOPHENOTHIAZINIUM COMPOUNDS | PROVENCE TECHNOLOGIES (FR) | 2008-01-17 | — | — | WO | claimed |
| US-4181128-A | CONTACTING CONCURRENTLY WITH HYDROGEN PEROXIDE, OXYGEN, LIGHT AND ELECTRICITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1980-01-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250222005-A1 | METHYLENE BLUE CONTAINING COMPOUNDS FOR THE TREATMENT OF METHAEMOGLOBINAEMIA | MB, HBB, HMBS | TSHR 4394/4885ACHE 3775/4885LMNA 746/4885 |
| US-20260048066-A1 | TREATMENT OF NEURODEGENERATIVE DISORDERS UTILISING METHYLTHIONINIUM (MT)-CONTAINING COMPOUNDS | MAPT, PARK7, TARDBP | TSHR 3126/4885ACHE 25/4885LMNA 3965/4885 |
| US-20250275980-A1 | METHYLTHIONINIUM SALT-CONTAINING COMPOSITIONS AND METHODS | SLC6A12, TPMT, SLC6A5 | TSHR 4311/4885ACHE 626/4885LMNA 1716/4885 |
| US-20260115200-A1 | Treatments Using Methylthioninium Salt, Liquid Mineral Blends, and/or Secondary Physiologically Active Compounds With Physiological Therapies | TPMT, SLC6A6, SLC6A12 | TSHR 2922/4885ACHE 135/4885LMNA 1461/4885 |
| US-20250302843-A1 | OPTIMISED DOSAGE OF DIAMINOPHENOTHIAZINES IN POPULATIONS | MAPT, TPMT, LMTK2 | TSHR 3363/4885ACHE 105/4885LMNA 1891/4885 |
| US-20250262219-A1 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | ACHE, BCHE, PNMT | TSHR 2540/4885ACHE 1/4885LMNA 4703/4885 |
| US-20260083747-A1 | COMPOSITIONS AND METHODS FOR SUPPORTING MITOCHONDRIAL HEALTH | UQCRC2, UQCRC1, MT-ND2 | TSHR 3769/4885ACHE 1715/4885LMNA 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.